Sagent Pharmaceuticals, Inc. has introduced oxaliplatin injection, USP, an antineoplastic agent, now in two liquid presentations. According to IMS, for the 12 months ending July 2014, the US market for oxaliplatin approximated $102 million. As with all products in Sagent's portfolio, oxaliplatin features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce the risk of medication errors.
"Jiangsu Hengrui Medicine Co. is a key strategic partnership for Sagent. We are pleased to launch oxaliplatin injection, USP, which is the second of many products we plan to launch under this partnership," said Jeffrey M. Yordon, chief executive officer and chairman of the Board.
Oxaliplatin injection, USP, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and for treatment of advanced colorectal cancer.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.
Jiangsu Hengrui Medicine Co., Ltd is an innovative pharmaceutical company and the leading provider of antineoplastic and surgical medications in China.